

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊 生物 科技 有 限 公 司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

RESIGNATION OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”) announces that, with effect from 21 May 2024, Mr. Lam Kai Kei (“**Mr. Lam**”) resigned as the Company Secretary and Authorised Representative of the Company.

Mr. Lam has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that should be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Company is in the process of identifying a suitable candidate to fill the vacancy of the Company Secretary and Authorised Representative caused by the resignation of Mr. Lam, and will publish further announcement once such appointment is confirmed.

The Board would like to extend its appreciation to Mr. Lam for his valuable contributions to the Company during his tenure of service.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman and Chief Executive Officer

Hong Kong, 21 May 2024

As at the date of this announcement, the Board consists of one executive Director, namely Mr. Lam Ka Chun and two independent non-executive Directors, namely Mr. Wan Bo and Mr. HE Tao.